ERBB2 and breast neoplasm: Breast tumours with HER-2 overexpression are resistant to hormonal therapy and alkylating agents, but more sensitive to anthracycline-based chemotherapy (Elledge et al, 1998; Ross and Fletcher, 1998; Hamilton and Piccart, 2000).